๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of mitoxantrone in locally advanced or metastatic adenoid cystic carcinomas (ACC) of the head and neck

โœ Scribed by Verweij, J.; de Mulder, P.; de Graeff, A.; Wildiers, J.; Vermorken, J.; Cognetti, F.; Kirkpatrick, A.; Lefebvre, J.; Schornagel, J.

Book ID
123456342
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
184 KB
Volume
29
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II study of esorubicin (4โ€ฒ -deoxyd
Phase II study of esorubicin (4โ€ฒ -deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma
โœ Sergio Frustaci; Giampietro Gasparini; Andrea Veronesi; Umberto Tirelli; Maria A ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer US ๐ŸŒ English โš– 232 KB

Sixteen patients with locally advanced or metastatic head and neck cancer were treated with esorubicin (4'-deoxydoxorubicin) at a dose of 30-35 mg/m 2 i.v. every 3 weeks. One patient was lost to the follow up after one cycle, whereas in the 15 evaluable cases a total of 34 courses were administered

Phase II study of mitoxantrone in advanc
Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck
โœ Stephen D. Williams; Robert Birch; Enrique Velez-Garcia; Richard Gams ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer US ๐ŸŒ English โš– 170 KB

A phase II study of mitoxantrone in squamous cell carcinoma of head and neck origin was conducted. Fiftythree evaluable patients were treated with this agent at a dosage of 5 mg/M2/week. The majority of patients were of high performance status. Twenty-seven patients had received previous chemotherap

Southwest Oncology Group study of mitoxa
Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck
โœ Douglas E. Mattox; Daniel D. Hoff; Stanley P. Balcerzak ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer US ๐ŸŒ English โš– 170 KB

Eighteen patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced adenoid cystic carcinoma of the head and neck. One patient had a complete response; there were no partial responses. Twelve patients had stable disease for 3 or more months. There was no significant anti-tu